<DOC>
	<DOCNO>NCT00506207</DOCNO>
	<brief_summary>This study open-label , single center , dose-escalating phase I study determine maximal tolerate dose recommend dose S-1 combine irinotecan/oxaliplatin patient unresectable metastatic colorectal gastric carcinoma .</brief_summary>
	<brief_title>A Phase I Study S-1 Plus Irinotecan Oxaliplatin Advanced Gastrointestinal Malignancy</brief_title>
	<detailed_description>Dose level escalate schedule following ; - S-1 ( level 1/2 , 3/4 , 5/6 : 60 , 70 , 80 mg/m2/day ) every 12-h p.o . day 1 ( even ) -15 ( morning ) - Irinotecan ( level 1,2/3 , 4/5 , 6 : 120 , 130 , 140 , 150 mg/m2 ) mix d5w normal saline 500 ml iv 90 min day 1 - Oxaliplatin 85 mg/m2 fix dose mixed d5w 250 ml iv infusion 2-h day 1 Treatment administer every 3 week . Start dose level 1 . Thereafter , dose level 2 , 3 , 4 , 5 , 6 . If dose-limiting toxicity ( DLT ) occur dose level 1 , dose level -1 follow Dose escalation continue one-third patient give cohort show dose-limiting toxicity ( DLT ) treatment cycle 1 . At least three patient enrol cohort . Before escalate next dose level , three patient receive least one treatment cycle . If none first three treated patient develop DLT first cycle specific dose level , dose escalation continue . If one first three treated patient develop DLT dose level , three additional patient enter dose level . If one six patient give level experience DLT , escalation proceed . The MTD define dose level least one-third patient experience DLT . The RD subsequent phase II study define precede dose level MTD attain . Intra-patient dose escalation permit . Treatment continue absence disease progression unacceptable toxicity maximum 12 cycle . For purpose determine MTD , DLT occur first cycle therapy consider . DLTs define follow ; - Grade 4 neutropenia last least 7 day grade 3 4 neutropenia associate fever  38.3C single axillary temperature 38 C 1-h - Grade 4 thrombocytopenia - Grade 3 4 non-hematological toxicity except alopecia , nausea/vomiting - Grade 3 4 nausea/vomiting reduce grade 1 aggressive antiemetic support - Inability patient take 75 % plan chemotherapy dose treatment period</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically confirm unresectable metastatic colorectal gastric carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable disease , accord RECIST criterion nonmeasurable disease Measurable lesion Previous adjuvant , palliative chemotherapy include 5FU , oxaliplatin irinotecan , molecular target therapy and/or radiotherapy allow Adequate major organ function Patients sign write informed consent study entry Prior history peripheral neuropathy Inadequate cardiovascular Serious concurrent infection nonmalignant illness Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix Psychiatric disorder would preclude compliance Pregnant , nurse woman patient reproductive potential without contraception Patients receive concomitant treatment drug interact S1 flucytosine , phenytoin , warfarin et al .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Gastrointestinal neoplasm</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>